People: Quintiles Transnational Holdings Inc (Q.N)

Q.N on New York Stock Exchange

54.99USD
25 Jul 2014
Price Change (% chg)

$0.15 (+0.27%)
Prev Close
$54.84
Open
$54.75
Day's High
$55.25
Day's Low
$54.45
Volume
60,182
Avg. Vol
170,899
52-wk High
$55.68
52-wk Low
$40.17

Search Stocks

Winstanly, Derek 

Brief Biography

Dr. Derek M. Winstanly M.D. is Executive Vice President - Chief Customer and Governance Officer of Quintiles Transnational Holdings Inc. Dr. Winstanly joined us in 1999 as President of Quintiles Japan and was responsible for the implementation of the Asia Pacific Contract Pharmaceutical Organization, including Pre-clinical, Clinical, Commercial, Academy and Informatics divisions. In 2002, he became chairman of Quintiles Japan and Regional Director for the Asia-Pacific region. In June 2005, he became our Executive Vice President, Strategic Business Partnerships. In his current role, Dr. Winstanly is responsible for the office of the chief medical and chief compliance officers and quality assurance. In addition, he is responsible for government affairs and is Chairman of the Asia-Pacific Regional Board. Prior to joining us, Dr. Winstanly worked for Glaxo Wellcome, plc, now GlaxoSmithKline, for 15 years. Dr. Winstanly first joined Glaxo South Africa, now GlaxoSmithKline South Africa, as Medical Director in charge of Clinical Development, Regulatory and Medical Affairs. After being named and serving as Chief Executive Officer of the South African company, Dr. Winstanly moved to the United Kingdom to accept the position of Director, Migraine & New Therapy areas, where he was responsible for the international commercial development of all products in these disease areas. Following the merger of Glaxo, Inc. and Burroughs, Wellcome & Co., he was appointed President of Nippon Wellcome, now GlaxoSmithKline K.K., in Japan. Dr. Winstanly qualified as a Medical Doctor MBChB at the University of Pretoria and is registered as a Medical Practitioner in both the United Kingdom and South Africa.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
838,400 -- 2,115,960 2,954,360

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Dennis Gillings

1,934,490

Thomas Pike

2,585,810

Kevin Gordon

4,153,570

James Erlinger

--

Derek Winstanly

2,954,360

Fred Cohen

--
As Of 30 Dec 2013
Search Stocks